topotecan hydrochloride  (TargetMol)

Journal: Ophthalmology Science

Article Title: Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma

doi: 10.1016/j.xops.2026.101226

Figure Lengend Snippet: Schematic representation of casting of the topotecan-loaded MSP. MSP = microneedle scleral patch; PDMS = polydimethylsiloxane.

Article Snippet: Topotecan hydrochloride was procured from TCI Chemicals Ltd.

Techniques:

Journal: Ophthalmology Science

Article Title: Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma

doi: 10.1016/j.xops.2026.101226

Figure Lengend Snippet: Representative digital images of the master mold (A) , PDMS mold (B) , and stereomicroscopic images of the topotecan MSP at different magnifications (C and D) , scanning electron microscopic images of the topotecan MSP (E) . MSP = microneedle scleral patch; PDMS = polydimethylsiloxane.

Article Snippet: Topotecan hydrochloride was procured from TCI Chemicals Ltd.

Techniques:

Journal: Ophthalmology Science

Article Title: Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma

doi: 10.1016/j.xops.2026.101226

Figure Lengend Snippet: Force-displacement curves obtained after compression test of blank and topotecan MSP (A) , and insertion test of blank and topotecan MSP into the excised goat sclera (B) . MSP = microneedle scleral patch.

Article Snippet: Topotecan hydrochloride was procured from TCI Chemicals Ltd.

Techniques:

Journal: Ophthalmology Science

Article Title: Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma

doi: 10.1016/j.xops.2026.101226

Figure Lengend Snippet: Representative Fourier-transform infrared spectra (A) , powder X-ray diffraction peak pattern (B) , differential scanning colorimetry thermograms (C) , and thermogravimetry analysis thermograms (D) of pure topotecan HCl, sodium hyaluronate, physical mixture (topotecan HCl + sodium hyaluronate), and topotecan MSP. The physical mixture was prepared with topotecan HCl: sodium hyaluronate ratio same as that in topotecan MSP. MSP = microneedle scleral patch.

Article Snippet: Topotecan hydrochloride was procured from TCI Chemicals Ltd.

Techniques: Fourier Transform Infrared Spectroscopy, Colorimetric Assay

Journal: Ophthalmology Science

Article Title: Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma

doi: 10.1016/j.xops.2026.101226

Figure Lengend Snippet: Scanning electron microscopic images of in vitro dissolution of topotecan MSP at different time points of 0 second, 5 seconds, 10 seconds, 15 seconds, 20 seconds, and 25 seconds. MSP = microneedle scleral patch.

Article Snippet: Topotecan hydrochloride was procured from TCI Chemicals Ltd.

Techniques: In Vitro, Dissolution

Journal: Ophthalmology Science

Article Title: Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma

doi: 10.1016/j.xops.2026.101226

Figure Lengend Snippet: Cumulative amount of topotecan permeated across the excised goat sclera after administration of the MSP and topotecan solution. Asterisk (∗) represents that the value is significantly different at P < 0.05 compared with topotecan solution. MSP = microneedle scleral patch.

Article Snippet: Topotecan hydrochloride was procured from TCI Chemicals Ltd.

Techniques:

Journal: Ophthalmology Science

Article Title: Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma

doi: 10.1016/j.xops.2026.101226

Figure Lengend Snippet: Ex vivo distribution of topotecan in various ocular tissues after application for 1 hour (A) and 4 hours (B) . MSP = microneedle scleral patch.

Article Snippet: Topotecan hydrochloride was procured from TCI Chemicals Ltd.

Techniques: Ex Vivo

Journal: Ophthalmology Science

Article Title: Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma

doi: 10.1016/j.xops.2026.101226

Figure Lengend Snippet: Topotecan distribution in different ocular tissues in rabbit eyes at different time points, including 1 hour (A) , 2 hours (B) , and 8 hours (C) , after intravitreal injection and MSP application. MSP = microneedle scleral patch.

Article Snippet: Topotecan hydrochloride was procured from TCI Chemicals Ltd.

Techniques: Injection

Journal: Ophthalmology Science

Article Title: Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma

doi: 10.1016/j.xops.2026.101226

Figure Lengend Snippet: Retinal fundus images of rabbit ocular model before and after application of topotecan MSP. MSP = microneedle scleral patch.

Article Snippet: Topotecan hydrochloride was procured from TCI Chemicals Ltd.

Techniques:

Journal: Pancreas

Article Title: Proteomic Characterization Reveals CYP2S1 as a Mediator of Drug Resistance in PDAC

doi: 10.1097/MPA.0000000000002553

Figure Lengend Snippet: Relevance of SN38 for CYP2S1 induction (A) TIPARP and CYP2S1 mRNA expression in response to SN38 treatment (1 μM, 72 h) in different PDAC cell lines (48 h for PACO 7). Control: DMSO. n=3, mean±SD. Multiple t tests with Holm-Sidak method, */**/***: adj. P <0.05/0.01/0.001. (B) Time-dependent induction of TIPARP and CYP2S1 mRNA expression upon SN38 treatment (1 μM) in HNF1A+ PDAC cell line PACO18. The mRNA levels were calculated relative to the DMSO control. Mean±SD. (C) AHR-ligand assay using HEK293T cells transfected with the Cignal AHR-GFP Reporter assay or a negative control. Fluorescence after treatment with vehicle control (PBS), positive control (dARNT) or SN38 (1 μM) for 24 hours. Increased fluorescence indicates successful binding to AHR. n=3, mean±SD. Unpaired t test,****: P <0.0001. (D) TIPARP and CYP2S1 mRNA expression after treatment of HNF1A+ PDAC cells with SN38 analog topotecan (1 μM, 72 h). Control: DMSO. n=3, mean±SD. Multiple t tests with Holm-Sidak method, ***: adj. P <0.001. (E) Impact of AHR knockdown (KD) on basal mRNA levels of AHR and CYP2S1. n=3, mean±SD. Multiple t tests with Holm-Sidak method, *: adj. P <0.05. No significant reduction of CYP2S1 level is observed. (F) CYP2S1 mRNA expression after treatment with DMSO control or SN38 (1 μM, 72 h) in 2 HNF1A+ PDAC cell lines w/o (NT) or with AHR knockdown (AHR KD). Controls: nontargeting (NT), DMSO. n=3, mean±SD. Multiple t tests with Holm-Sidak method, **/***: adj. P <0.01/0.001. Knockdown of AHR impairs the inducibility of CYP2S1 by SN38 in PDAC cells. (G) Impact of transient HNF4A knockdown on relative HNF4A or CYP2S1 mRNA expression in HNF1A+ PACO10. Control: non-targeting (NT). n=3, mean±SD. Multiple t tests with Holm-Sidak method, **: adj. P <0.01. (H) Relative CYP2S1 mRNA expression after treatment with DMSO control or SN38 (1 μM, 72 h) in 2 HNF1A+ PDAC cell lines with (siHNF4A) or w/o (siNT) transient HNF4A knockdown. Controls: nontargeting (siNT), DMSO. n=3, mean±SD. Multiple t tests with Holm-Sidak method, **/***: adj. P <0.01/0.001.

Article Snippet: PACO cells were grown for 48 hours, before fresh medium comprising the respective compound was added, that is, β-Naphthoflavone (bNF, MFCD00004985, Sigma), 3-Methylcholanthrene (3MC, 56-49-5, Sigma), Benzo[a]pyrene (BaP, 50-32-8, Sigma), 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD, ARCD0413, American RadiolabeledChemicals Inc.), AhR Inhibitor (Merck Millipore, 182706-5MG), SN-38 (SN-38 glucuronide, 121080-63-5, Santa Cruz), or topotecan (topotecan hydrochloride, sc-204919, Santa Cruz).

Techniques: Expressing, Control, Transfection, Reporter Assay, Negative Control, Fluorescence, Positive Control, Binding Assay, Knockdown

Journal: Molecular Psychiatry

Article Title: Frontotemporal dementia patient-derived iPSC neurons show cell pathological hallmarks and evidence for synaptic dysfunction and DNA damage

doi: 10.1038/s41380-025-03272-x

Figure Lengend Snippet: NUPR2 , potentially related to the DNA damage pathway, is the only differentially expressed gene when comparing the C9-HRE and sporadic FTD neurons ( A ). Both sporadic (C9-) and C9-HRE-carrying FTD (C9+) neurons display nuclei, which are significantly rounder in shape as well as significantly smaller compared to healthy neuron nuclei, indicated by altered nuclear eccentricity ( B ), and a higher number of micronuclei ( C ). A representative image of a micronucleus next to the nucleus is shown (arrow). Kruskal-Wallis test followed by Dunn’s multiple comparisons test was used. n [Control] = 74; n [C9−] = 17; n [C9+] = 21. In addition, the distribution of larger and smaller sized nuclei is different in FTD neurons than that in control neurons ( D – F ). Representative images of control, C9-, and C9+ neurons treated with vehicle (upper panel) or 10 µM topotecan (lower panel). The neurons were stained with antibodies against MAP2 (red) and γH2A.X (green). Nuclei were stained with DAPI (blue) ( G ). Topotecan treatment significantly increases the number of γH2A.X-positive foci in the nuclei in all neurons, indicating increased DNA damage. At baseline, C9+ neurons display a slightly higher number of γH2A.X foci compared to control neurons, although this difference is not statistically significant ( H – J ). Kruskal-Wallis test followed by Dunn’s multiple comparisons test was used. n [Control] = 26–28; n [C9−] = 15–18; n [C9+] = 44–64. Statistically significant differences are shown as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

Article Snippet: To study the DNA damage response, iPSC-derived neurons were treated with 10 μM topotecan (Topotecan hydrochloride, Tocris, 4562) or DMSO vehicle for 1 h. The cells were fixed with 4% PFA and stained with conjugated MAP2 and γH2A.X antibody as described above.

Techniques: Control, Staining

Journal: bioRxiv

Article Title: A Human Angelman Syndrome Class II Pluripotent Stem Cell line with Fluorescent Paternal UBE3A Reporter

doi: 10.1101/2025.07.12.664539

Figure Lengend Snippet: Reporter fluorescence changes in response to topoisomerase inhibitors. Flow cytometry histograms comparing green fluorescence intensities in 17-week-old reporter organoids exposed to A) 1 µM topotecan, B) 1 µM irinotecan, and C) 0.2% DMSO in water (vehicle control). The parental and reporter iPSCs were used to determine the GF +/-gate. a.u. - arbitrary units.

Article Snippet: Topotecan hydrochloride and irinotecan hydrochloride (both from Molcan Corporation) were directly added to 17-week-old AS reporter organoids at a final concentration of 1μM in culture.

Techniques: Fluorescence, Flow Cytometry, Control